Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2012

European Journal of Cancer

Volumn 48, Issue 15, 2012, Pages 2375-2390

  Garbe, Claus ^a   Peris, Ketty ^b   Hauschild, Axel ^c   Saiag, Philippe ^d   Middleton, Mark ^e   Spatz, Alan ^f   Grob, Jean Jacques ^g   Malvehy, Josep ^h   Newton Bishop, Julia ⁱ   Stratigos, Alexander ^j   Pehamberger, Hubert ^k   Eggermont, Alexander M ^l  

^a Department of Dermatology   (Germany)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MCGILL UNIVERSITY   (Canada)

^g University Department of Dermatology   (France)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

^j UNIVERSITY OF ATHENS   (Greece)

^k Universitatsklinik fur Dermatologie   (Austria)

^l INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Adjuvant treatment; Cutaneous melanoma; Excisional margins; Interferon ; Metastasectomy; Sentinel lymph node dissection; Systemic treatment; Tumour thickness

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; B RAF KINASE; BCG VACCINE; CARMUSTINE; CISPLATIN; CYTOSTATIC AGENT; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3 ANTIBODY; PACLITAXEL; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; TREOSULFAN; UNCLASSIFIED DRUG; VEMURAFENIB; VINDESINE;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALIGNANT LENTIGO; MEDICAL TERMINOLOGY; MELANOMA; METASTASIS RESECTION; MICROMETASTASIS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE N RAS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN METASTASIS; SKIN NODULE; SKIN SURGERY; SURVIVAL TIME; UVEA MELANOMA;

COMBINED MODALITY THERAPY; EUROPEAN UNION; HUMANS; LYMPH NODE EXCISION; MALE; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84866730315     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.06.013     Document Type: Article

References (157)

1. C. Garbe, K. Peris, and A. Hauschild Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline Eur J Cancer 46 2 2010 270 283
2. C. Garbe, A. Hauschild, and M. Volkenandt Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting Melanoma Res 18 2 2008 152 160
3. C. Garbe, A. Hauschild, and M. Volkenandt Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma Melanoma Res 18 1 2008 61 67
4. C. Garbe, A. Hauschild, and M. Volkenandt Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma Melanoma Res 17 6 2007 393 399
5. R. Dummer, M. Guggenheim, A.W. Arnold, R. Braun, and R. von Moos Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma Swiss Med Wkly 15 141 2011 w13320 10.4414/smw.2011.13320
6. J.R. Marsden, J.A. Newton-Bishop, and L. Burrows Revised U.K. guidelines for the management of cutaneous melanoma 2010 Br J Dermatol 163 2 2010 238 256
7. P. Saiag, L. Bosquet, and B. Guillot Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report Eur J Dermatol 17 4 2007 325 331
8. U. Leiter, and C. Garbe Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight Adv Exp Med Biol 624 2008 89 103
9. C. Garbe, and U. Leiter Melanoma epidemiology and trends Clin Dermatol 27 1 2009 3 9
10. J. Bauer, and C. Garbe Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data Pigment Cell Res 16 3 2003 297 306
11. C. Garbe, P. Buttner, and J. Weiss Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society J Invest Dermatol 102 5 1994 700 705
12. J.J. Grob, J. Gouvernet, and D. Aymar Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma Cancer 66 2 1990 387 395
13. E.A. Holly, J.W. Kelly, S.N. Shpall, and S.H. Chiu Number of melanocytic nevi as a major risk factor for malignant melanoma J Am Acad Dermatol 17 3 1987 459 468
14. J.N. Bishop, M. Harland, J. Randerson-Moor, and D.T. Bishop Management of familial melanoma Lancet Oncol 8 1 2007 46 54
15. F.A. de Snoo, M.W. Kroon, and W. Bergman From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients J Am Acad Dermatol 56 5 2007 748 752
16. J.A. Curtin, J. Fridlyand, and T. Kageshita Distinct sets of genetic alterations in melanoma N Engl J Med 353 20 2005 2135 2147
17. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 26 2006 4340 4346
18. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 10 2004 998 1012
19. W.H. Clark Jr., L. From, E.A. Bernardino, and M.C. Mihm The histogenesis and biologic behavior of primary human malignant melanomas of the skin Cancer Res 29 3 1969 705 727
20. M.C. Mihm Jr., W.H. Clark Jr., and L. From The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas N Engl J Med 284 19 1971 1078 1082
21. V.J. McGovern, M.C. Mihm Jr., and C. Bailly The classification of malignant melanoma and its histologic reporting Cancer 32 6 1973 1446 1457
22. A. Viros, J. Fridlyand, and J. Bauer Improving melanoma classification by integrating genetic and morphologic features PLoS Med 5 6 2008 e120
23. D.C. Whiteman, W.J. Pavan, and B.C. Bastian The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin Pigment Cell Melanoma Res 24 5 2011 879 897
24. J.L. Maldonado, J. Fridlyand, and H. Patel Determinants of BRAF mutations in primary melanomas J Natl Cancer Inst 95 24 2003 1878 1890
25. D. Handolias, R. Salemi, and W. Murray Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure Pigment Cell Melanoma Res 23 2 2010 210 215
26. K. Omholt, E. Grafstrom, L. Kanter-Lewensohn, J. Hansson, and B.K. Ragnarsson-Olding KIT pathway alterations in mucosal melanomas of the vulva and other sites Clin Cancer Res 17 12 2011 3933 3942
27. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
28. J.F. Thompson, S.J. Soong, and C.M. Balch Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database J Clin Oncol 29 16 2011 2199 2205
29. A. Spatz, M.G. Cook, and D.E. Elder Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas Eur J Cancer 39 13 2003 1861 1865
30. R.A. Scolyer, J.F. Thompson, H.M. Shaw, and S.W. McCarthy The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma J Cutan Pathol 33 5 2006 395 396
31. A.C. Green, P. Baade, M. Coory, J.F. Aitken, and M. Smithers Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia J Clin Oncol 30 13 2012 1462 1467
32. A. Joosse, S. Collette, and S. Suciu Superior Outcome of Women With Stage I/II Cutaneous Melanoma: Pooled Analysis of Four European Organisation for Research and Treatment of Cancer Phase III Trials J Clin Oncol 30 18 2012 2240 2247
33. D.L. Morton, D.R. Wen, and J.H. Wong Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 4 1992 392 399
34. D.L. Morton, J.F. Thompson, and A.J. Cochran Sentinel-node biopsy or nodal observation in melanoma N Engl J Med 355 13 2006 1307 1317
35. H. Kittler, H. Pehamberger, K. Wolff, and M. Binder Diagnostic accuracy of dermoscopy Lancet Oncol 3 3 2002 159 165
36. S.W. Menzies, C. Ingvar, and W.H. McCarthy A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma Melanoma Res 6 1 1996 55 62
37. F. Nachbar, W. Stolz, and T. Merkle The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions J Am Acad Dermatol 30 4 1994 551 559
38. G. Argenziano, C. Longo, and A. Cameron Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma Br J Dermatol 165 6 2011 1251 1255
39. G. Argenziano, H.P. Soyer, and S. Chimenti Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet J Am Acad Dermatol 48 5 2003 679 693
40. H. Kittler, P. Guitera, and E. Riedl Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging Arch Dermatol 142 9 2006 1113 1119
41. S.W. Menzies, J. Kreusch, and K. Byth Dermoscopic evaluation of amelanotic and hypomelanotic melanoma Arch Dermatol 144 9 2008 1120 1127
42. F.J. Moloney, and S.W. Menzies Key points in the dermoscopic diagnosis of hypomelanotic melanoma and nodular melanoma J Dermatol 38 1 2011 10 15
43. M.A. Pizzichetta, I. Stanganelli, and R. Bono Dermoscopic features of difficult melanoma Dermatol Surg 33 1 2007 91 99
44. W. Stolz, R. Schiffner, and W.H. Burgdorf Dermatoscopy for facial pigmented skin lesions Clin Dermatol 20 3 2002 276 278
45. R. Schiffner, J. Schiffner-Rohe, and T. Vogt Improvement of early recognition of lentigo maligna using dermatoscopy J Am Acad Dermatol 42 1 Pt. 1 2000 25 32
46. P. Pralong, E. Bathelier, and S. Dalle Dermoscopy of lentigo maligna melanoma: report of 125 cases Br J Dermatol 2012 10 2133
47. H. Koga, and T. Saida Revised 3-step dermoscopic algorithm for the management of acral melanocytic lesions Arch Dermatol 147 6 2011 741 743
48. T. Saida Malignant melanoma in situ on the sole of the foot. Its clinical and histopathologic characteristics Am J Dermatopathol 11 2 1989 124 130
49. T. Saida, S. Oguchi, and A. Miyazaki Dermoscopy for acral pigmented skin lesions Clin Dermatol 20 3 2002 279 285
50. T. Saida, H. Koga, and H. Uhara Key points in dermoscopic differentiation between early acral melanoma and acral nevus J Dermatol 38 1 2011 25 34
51. D. Altamura, E. Altobelli, and T. Micantonio Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy Arch Dermatol 142 9 2006 1123 1128
52. H. Kittler, and M. Binder Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits Arch Dermatol 138 10 2002 1379
53. J. Bauer, A. Blum, U. Strohhacker, and C. Garbe Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy Br J Dermatol 152 1 2005 87 92
54. H.A. Haenssle, U. Krueger, and C. Vente Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma J Invest Dermatol 126 5 2006 980 985
55. C. Garbe, A. Paul, and H. Kohler-Späth Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy J Clin Oncol 21 2003 520 529
56. D.J. Ruiter, A. Spatz, J.J. van den Oord, and M.G. Cook Pathologic staging of melanoma Semin Oncol 29 4 2002 370 381
57. C. Garbe, T.K. Eigentler, U. Keilholz, A. Hauschild, and J.M. Kirkwood Systematic review of medical treatment in melanoma: current status and future prospects Oncologist 16 1 2011 5 24
58. M. Colombino, M. Capone, and A. Lissia BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma J Clin Oncol 30 20 2012 2522 2529
59. R.D. Carvajal, C.R. Antonescu, and J.D. Wolchok KIT as a therapeutic target in metastatic melanoma JAMA 305 22 2011 2327 2334
60. J. Guo, L. Si, and Y. Kong Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J Clin Oncol 29 21 2011 2904 2909
61. C. Garbe, U. Leiter, and U. Ellwanger Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients Cancer 97 7 2003 1737 1745
62. B. Schlagenhauff, B. Schittek, and U. Ellwanger Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res 10 5 2000 451 459
63. A. Hauschild, F. Rosien, and S. Lischner Surgical standards in the primary care of melanoma patients Onkologie 26 3 2003 218 222
64. R.C. Martin, C.R. Scoggins, and M.I. Ross Is incisional biopsy of melanoma harmful? Am J Surg 190 6 2005 913 917
65. A. Pflugfelder, B. Weide, and T.K. Eigentler Incisional biopsy and melanoma prognosis: facts and controversies Clin Dermatol 28 3 2010 316 318
66. D.G. Coit, R. Andtbacka, and C.K. Bichakjian Melanoma J Natl Compr Canc Netw 7 3 2009 250 275
67. The Cancer Council Australia and Australian Cancer Network SaNZGGW. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand; 2008
68. S. Negrier, P. Saiag, and B. Guillot Guidelines for clinical practice. Standards, options and recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 consensus conference and the 1998 standards, options, and recommendations Ann Dermatol Venereol 132 12 Pt. 2 2005 10S3-85
69. The Cancer Council Australia and Australian Cancer Network SaNZGGW. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand; 2008.
70. M. Moehrle, K. Dietz, C. Garbe, and H. Breuninger Conventional histology vs. three-dimensional histology in lentigo maligna melanoma Br J Dermatol 154 3 2006 453 459
71. M.A. Cotter, J.K. McKenna, and G.M. Bowen Treatment of lentigo maligna with imiquimod before staged excision Dermatol Surg 34 2 2008 147 151
72. U.V. Buettiker, N.Y. Yawalkar, L.R. Braathen, and R.E. Hunger Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients Arch Dermatol 144 7 2008 943 945
73. M.H. Mahoney, M.G. Joseph, and C. Temple Topical imiquimod therapy for lentigo maligna Ann Plast Surg 61 4 2008 419 424
74. M. Moehrle, S. Metzger, and W. Schippert "Functional" surgery in subungual melanoma Dermatol Surg 29 4 2003 366 374
75. H. Breuninger, B. Schlagenhauff, W. Stroebel, G. Schaumburg-Lever, and G. Rassner Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation Am J Surg Pathol 23 12 1999 1493 1498
76. C.L. Temple, and J.P. Arlette Mohs micrographic surgery in the treatment of lentigo maligna and melanoma J Surg Oncol 94 4 2006 287 292
77. D.L. Morton, D.R. Wen, and J.H. Wong Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 4 1992 392 399
78. D.L. Morton, J.F. Thompson, and A.J. Cochran Sentinel-node biopsy or nodal observation in melanoma N Engl J Med 355 13 2006 1307 1317
79. J.F. Thompson, and H.M. Shaw Sentinel node mapping for melanoma: results of trials and current applications Surg Oncol Clin N Am 16 1 2007 35 54
80. D.L. Morton, L. Wanek, J.A. Nizze, R.M. Elashoff, and J.H. Wong Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic Ann Surg 214 4 1991 491 499
81. D. Lienard, A.M. Eggermont, and H.S. Koops Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study Melanoma Res 9 5 1999 491 502
82. R.P. Petersen, S.I. Hanish, and J.C. Haney Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma J Thorac Cardiovasc Surg 133 1 2007 104 110
83. A. Sanki, R.A. Scolyer, and J.F. Thompson Surgery for melanoma metastases of the gastrointestinal tract: indications and results Eur J Surg Oncol 35 3 2009 313 319
84. T.C. Chua, A. Saxena, and D.L. Morris Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases Ann Acad Med Singapore 39 8 2010 634 639
85. N. Wasif, S.P. Bagaria, P. Ray, and D.L. Morton Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes J Surg Oncol 104 2 2011 111 115
86. S.J. Moschos, H.D. Edington, and S.R. Land Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol 24 19 2006 3164 3171
87. B.H. Burmeister, M.A. Henderson, and J. Ainslie Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial Lancet Oncol 13 6 2012 589 597
88. K.R. Olivier, S.E. Schild, C.G. Morris, P.D. Brown, and S.N. Markovic A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma Cancer 110 8 2007 1791 1795
89. J. Overgaard, D. Gonzalez Gonzalez, and M.C. Hulshof Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology, 1996 Int J Hyperthermia 25 5 2009 323 334
90. W.R. Rate, L.J. Solin, and A.T. Turrisi Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression Int J Radiat Oncol Biol Phys 15 4 1988 859 864
91. H.R. Katz The results of different fractionation schemes in the palliative irradiation of metastatic melanoma Int J Radiat Oncol Biol Phys 7 7 1981 907 911
92. J.B. Konefal, B. Emami, and M.V. Pilepich Analysis of dose fractionation in the palliation of metastases from malignant melanoma Cancer 61 2 1988 243 246
93. Y.M. Kirova, J. Chen, L.I. Rabarijaona, Y. Piedbois, and J.P. Le Bourgeois Radiotherapy as palliative treatment for metastatic melanoma Melanoma Res 9 6 1999 611 613
94. D.W. Andrews, C.B. Scott, and P.W. Sperduto Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial Lancet 363 9422 2004 1665 1672
95. R.A. Patchell, P.A. Tibbs, and W.F. Regine Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial JAMA 280 17 1998 1485 1489
96. C. Gaudy-Marqueste, J.M. Regis, and X. Muracciole Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy Int J Radiat Oncol Biol Phys 65 3 2006 809 816
97. N. Kased, K. Huang, and J.L. Nakamura Gamma knife radiosurgery for brainstem metastases: the UCSF experience J Neurooncol 86 2 2008 195 205
98. D.H. Lawson Choices in adjuvant therapy of melanoma Cancer Control 12 4 2005 236 241
99. M.S. Sabel, and V.K. Sondak Pros and cons of adjuvant interferon in the treatment of melanoma Oncologist 8 5 2003 451 458
100. D. Davar, A.A. Tarhini, and J.M. Kirkwood Adjuvant therapy for melanoma Cancer J 18 2 2012 192 202
101. A. Hauschild, H. Gogas, and A. Tarhini Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion Cancer 112 5 2008 982 994
102. H.S. Koops, M. Vaglini, and S. Suciu Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 J Clin Oncol 16 9 1998 2906 2912
103. E.P. Tjin, D. Konijnenberg, and G. Krebbers T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy Clin Cancer Res 17 17 2011 5736 5747
104. H. Pehamberger, H.P. Soyer, and A. Steiner Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group J Clin Oncol 16 4 1998 1425 1429
105. C. Garbe, P. Radny, and R. Linse Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective- randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis Ann Oncol 19 6 2008 1195 1201
106. U.R. Kleeberg, S. Suciu, and E.B. Brocker Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis Eur J Cancer 40 3 2004 390 402
107. B.W. Hancock, K. Wheatley, and S. Harris Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma J Clin Oncol 22 1 2004 53 61
108. N. Cascinelli, F. Belli, and R.M. Mackie Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial Lancet 358 9285 2001 866 869
109. D.A. Cameron, M.C. Cornbleet, and R.M. Mackie Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study Br J Cancer 84 9 2001 1146 1149
110. J.M. Kirkwood, J.G. Ibrahim, and V.K. Sondak High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 12 2000 2444 2458
111. J.J. Grob, B. Dreno, and P. de la Salmoniere Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma Lancet 351 9120 1998 1905 1910
112. J. Hansson, S. Aamdal, and L. Bastholt Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial Lancet Oncol 12 2 2011 144 152
113. A.M. Eggermont, S. Suciu, and R. MacKie Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 9492 2005 1189 1196
114. J.M. Kirkwood, M.H. Strawderman, and M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1 1996 7 17
115. E.T. Creagan, R.J. Dalton, and D.L. Ahmann Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 11 1995 2776 2783
116. A.M. Eggermont, S. Suciu, and M. Santinami Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 9633 2008 117 126
117. S. Mocellin, S. Pasquali, C.R. Rossi, and D. Nitti Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 102 7 2010 493 501
118. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
119. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
120. J.M. Ko, and D.E. Fisher A new era: melanoma genetics and therapeutics J Pathol 223 2 2011 241 250
121. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 8 2012 707 714
122. J.G. Greger, S.D. Eastman, and V. Zhang Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol Cancer Ther 11 4 2012 909 920
123. G.S. Falchook, G.V. Long, and R. Kurzrock Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 379 9829 2012 1893 1901
124. A. Hauschild, J.J. Grob, and L.V. Demidov Dabrafenib shows superior efficacy to dacarbazine in BRAF mutated metastatic melanoma Lancet 380 9839 2012 358 365
125. K.T. Flaherty, C. Robert, and P. Hersey Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2 2012 107 114
126. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007;25(18s):8508.
127. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 26 2011 2517 2526
128. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
129. A. Ribas Tumor immunotherapy directed at PD-1 N Engl J Med 366 26 2012 2517 2519
130. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
131. A.Y. Bedikian, R.C. DeConti, and R. Conry Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma Ann Oncol 22 4 2011 787 793
132. P.M. Patel, S. Suciu, and L. Mortier Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032) Eur J Cancer 47 10 2011 1476 1483
133. A.Y. Bedikian, M. Millward, and H. Pehamberger Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group J Clin Oncol 24 29 2006 4738 4745
134. M.R. Middleton, J.J. Grob, and N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 1 2000 158 166
135. U. Ringborg, C.M. Rudenstam, and J. Hansson Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study Med Oncol Tumor Pharmacother 6 4 1989 285 289
136. V. Chiarion Sileni, R. Nortilli, and S.M. Aversa Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients Melanoma Res 11 2 2001 189 196
137. A.M. Young, J. Marsden, A. Goodman, A. Burton, and J.A. Dunn Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma Clin Oncol (R Coll Radiol) 13 6 2001 458 465
138. N.M. Bleehen, E.S. Newlands, and S.M. Lee Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 4 1995 910 913
139. C. Jacquillat, D. Khayat, and P. Banzet Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma Cancer Chemother Pharmacol 25 4 1990 263 266
140. F. Mornex, L. Thomas, and P. Mohr A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma Melanoma Res 13 1 2003 97 103
141. R.A. Nelimark, B.A. Peterson, G.J. Vosika, and J.A. Conroy Vindesine for metastatic malignant melanoma. A phase II trial Am J Clin Oncol 6 5 1983 Oct 561 564
142. J. Carmichael, R.J. Atkinson, and K.C. Calman A multicentre phase II trial of vindesine in malignant melanoma Eur J Cancer Clin Oncol 18 12 1982 1293 1295
143. T.K. Eigentler, U.M. Caroli, P. Radny, and C. Garbe Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials Lancet Oncol 4 12 2003 748 759
144. D. Nashan, M.L. Muller, S. Grabbe, S. Wustlich, and A. Enk Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine J Eur Acad Dermatol Venereol 21 10 2007 1305 1318
145. S. Gundersen Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study Cancer Treat Rep 71 11 1987 997 999
146. D. Pectasides, H. Yianniotis, and N. Alevizakos Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin Br J Cancer 60 4 1989 627 629
147. U. Jungnelius, U. Ringborg, and S. Aamdal Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial Eur J Cancer 34 9 1998 1368 1374
148. C.F. Verschraegen, U.R. Kleeberg, and J. Mulder Combination of cisplatin, vindesine and dacarbazine in advanced malignant melanoma Cancer 62 1988 1061 1065
149. E.F. McClay, M.J. Mastrangelo, R.E. Bellet, and D. Berd Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma Cancer Treat Rep 71 5 1987 465 469
150. P.B. Chapman, L.H. Einhorn, and M.L. Meyers Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 17 9 1999 2745 2751
151. E.T. Creagan, V.J. Suman, and R.J. Dalton Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma J Clin Oncol 17 6 1999 1884 1890
152. R.D. Rao, S.G. Holtan, and J.N. Ingle Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma Cancer 106 2 2006 375 382
153. S. Leyvraz, V. Spataro, and J. Bauer Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy J Clin Oncol 15 7 1997 2589 2595
154. G. Egerer, T. Lehnert, and R. Max Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients Int J Clin Oncol 6 1 2001 25 28
155. R. Siegel, A. Hauschild, and C. Kettelhack Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma Eur J Surg Oncol 33 5 2007 627 632
156. C. Pfohler, I.A. Cree, and S. Ugurel Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study Anticancer Drugs 14 5 2003 337 340
157. U. Hofmann, M. Szedlak, W. Rittgen, E.G. Jung, and D. Schadendorf Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival Br J Cancer 87 2 2002 151 157